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Objectives: Management with vitamin K antagonists (VKAs) has been an effec-
tive and cost-effective strategy for stroke prevention in atrial fibrillation (AF) but 
is associated with shortcomings. Novel oral anticoagulants (NOACs) were devel-
oped with the aims of no monitoring requirement and improved effectiveness 
and safety profiles. Economic evaluations require the comparison of all relevant 
options. However, there are no randomized controlled trials (RCTs) directly compar-
ing these agents. In such cases, indirect treatment comparison (ITC) can be used to 
synthesize indirect comparative evidence. Through ITC-based evidence synthesis, 
the cost-effectiveness of all available NOACs for stroke prevention in AF patients 
may be evaluated. MethOds: ITC models were based on RCTs data comparing 
dabigratran, rivaroxaban, or apixaban with VKA treatment. Relative effectiveness 
was estimated for stroke/systemic embolism, intracranial hemorrhage, myocar-
dial infarction, extracranial hemorrhage, and minor bleeding. A Markov model was 
developed using ITC-synthesized evidence with VKA as the baseline. Health utili-
ties were collected from international sources whereas costs and mortality data 
were extracted from Dutch sources. Univariate and probabilistic sensitivity analy-
ses (PSA) were conducted on the base-case incremental cost-effectiveness ratio 
(ICER). Results: The ICERs for dabigatran, apixaban, and rivaroxaban compared to 
VKA were € 12,146/QALY, € 12,488/QALY, and € 24,124/QALY, respectively. Sensitivity 
analysis using the upper and lower limits of the 95% confidence interval for abso-
lute stroke risk with VKA treatment resulted in ICERs that varied drastically from 
dominance for VKA to being dominated by all NOACs. This is likely due to the large 
uncertainty observed between the baseline risk profiles of the VKA arms in the 
three RCTs. The options with the highest probabilities of cost-effectiveness in PSA 
were VKA at thresholds under € 13,000/QALY and dabigatran or apixaban at thresh-
olds above this mark. cOnclusiOns: Dabigatran and apixaban were shown to be 
cost-effective options for AF patients in The Netherlands. However, these results 
were strongly influenced by uncertainty around stroke risk with VKA treatment.
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Objectives: Outcomes trials are currently underway to establish the effects of 
DPP-4 inhibitors on major adverse cardiovascular events (MACE), but to-date no 
major clinical trial has published results. Using simulations, we evaluated the 
effectiveness of DPP-4 inhibitors in preventing MACE in two populations with type 
2 diabetes, relative to the standard of care. MethOds: We used the Archimedes 
ARCHeS platform to simulate two clinical trials of virtual individuals with diag-
nosed type 2 diabetes (N= 11,000 each). The DPP-4 class was modeled with a meta-
analysis of HbA1c and weight change, pooling results from published trials. The 
study treatments were added-on to standard care. The first simulated trial examined 
subjects with elevated cardiovascular (CV) risk, based on established CV disease 
or multiple risk factors. The second considered individuals on metformin mono-
therapy with HbA1c ≥ 7%. We tracked changes in biomarkers and outcomes for 
20 years. Results: The DPP-4 class was associated with HbA1c drops of 0.66% 
[0.71% , 0.62% ] in the elevated CV risk population and 0.71% [0.75%,0.67%] in the 
metformin add-on population; and a weight drop of 0.14 [0.36,-0.07] kg in both 
cohorts. The biomarker benefits produced a relative risk (RR) for MACE at 5 years 
of 0.977 [0.968, 0.986] and 0.962 [0.949, 0.975] for the elevated CV risk population 
and metformin add-on population, respectively. The number needed to treat to 
prevent one occurrence of MACE at 5 years was 327 [233,550] in the elevated CV risk 
population. cOnclusiOns: Our simulated study suggests that DPP-4 inhibitors do 
not increase the risk of MACE relative to the standard of care in a population with 
elevated CV risk, and a representative diabetic metformin monotherapy population. 
This study provides insights on the long term benefits of DPP-4 inhibitors, and will 
support interpretation of the CV safety trial results likely to be published soon.
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Objectives: Given the absence of head-to-head studies, this review summarized 
indirect treatment comparison studies of oral anticoagulants (OACs) for the pre-
vention of stroke in patients with nonvalvular atrial fibrillation (NVAF). MethOds: 
Eligible English-language studies published up to May 31, 2013 were identified 
from electronic databases, Medline, EMBASE and Cochrane Library. Studies were 
included if the indirect comparison involved at least two OACs currently on the 
market with the common comparator warfarin. The search yielded ten pub-
lished studies and one in press study was obtained. Results: Eleven indirect 
comparison studies, based on data from three phase III (RE-LY, ROCKET-AF, and 
ARISTOTLE) and one phase II (PETRO) clinical trial, was reviewed. Six pairwise 
comparisons were reviewed across studies: any/all OACs vs. warfarin, apixaban 
vs. dabigatran 110mg, apixaban vs. dabigatran 150mg, apixaban vs. rivaroxaban, 
dabigatran 110mg vs. rivaroxaban, and dabigatran 110mg vs. rivaroxaban. OACs as 
a whole were found to have significantly better bleeding and efficacy endpoints 
when compared with warfarin. Apixaban and dabigatran 110mg were found to 
have significantly reduced risk of multiple bleeding endpoints when compared 
with rivaroxaban and dabigatran 150mg. Dabigatran 150mg was found to have 
significantly decreased risk of multiple efficacy endpoints when compared with 
rivaroxaban. Three studies compared discontinuation rates. Apixaban and rivar-
oxaban were found to have significantly lower discontinuation rates compared 
with both doses of dabigatran. Apixaban was also found to have a significantly 
lower discontinuation rate compared with rivaroxaban. cOnclusiOns: Apixaban, 
Hospital with suspected gynaecological malignancy and who fulfilled the inclu-
sion criteria were recruited for the study. All patients with BMI less than 35 received 
Tinzaparin (4500 IU) once daily injection while those with BMI more than 35 received a 
higher dose (7500 IU). Two days post surgery; venous blood samples were collected for 
anti-Xa analysis 4 hours post Tinzaparin injection. Results: The majority of patients 
received Tinzaparin of 4500 IU. The mean anti-Xa level in the malignant group was 
0.191 IU/ml while in the benign group the level was 0.1740 IU/ml. There was no dif-
ference between the two groups. In the malignant group, the number of cases with 
peak anti-Xa levels below 0.1IU/ml was slightly higher than in the benign group. One 
patient with malignant disease developed VTE, in the immediate postoperative period 
and showed a low peak anti-Xa level (0.06IU/ml). cOnclusiOns: The results of this 
study show that Tinzaparin prophylaxis provides adequate peak anti-Xa levels in the 
majority of gynae-oncology patients post surgery and is unlikely to be responsible 
for the high rates of VTE in cancer patients in the immediate post operative period. 
Larger studies are required to confirm this.
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Objectives: Pill splitting is a common problem in Hong Kong public hospitals for 
flexible dose adjustment and cost containment, especially for chronic diseases’ 
treatments such as hypertension, diabetes mellitus. The current study aimed 
to determine the importance of education on the proper way of pill splitting for 
elderly in Hong Kong by exploring their habits of pill splitting, evaluating their 
knowledge on pill cutting and investigating the impact of improper pill cutting 
habit. MethOds: Survey was conducted on elderly taking selected drugs require 
splitting (Metformin, Atenolol and Amlodipine) in 5 elderly centers. The survey 
focuses on habits and knowledge regarding pill cutting. Elderly subjects were asked 
to cut 3 pills that they were currently taking in their own ways. After proper educa-
tion, they were asked to cut another 3 pills with a pill cutter. The collected sample 
were then weighed and analyzed. The result was then compared with ideal value 
of half of the whole pill. Results: From the survey, 72% of the elderly have never 
received any education on pill cutting. Above half consider pill cutting troublesome. 
About half thought that all kinds of pills can be cut without affecting the expected 
effect. 80% cut pills for more than one dose each time, including 44% cut pills for 7 
days’ doses each time. From the experiment, the results of Metformin and Atenolol 
show that the cut drug samples’ weights deviate a lot from the ideal value (50% of 
the whole pill) before education. After education, the samples’ weights get closer 
to the ideal value. However, the result of Amlodipine does not show significant dif-
ference. cOnclusiOns: Education can improve the accuracy of dose in regimen 
require pill splitting. Elderly in Hong Kong do not receive enough education on the 
proper way of pill splitting from the health care giver.
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Objectives: European guidelines recommend statins as first-line treatment for 
elevated cholesterol in patients at high cardiovascular (CV) risk; however, many 
patients do not attain guideline-recommended goals on statin monotherapy. As 
atorvastatin is now generically-available and its use is likely to increase, we exam-
ined recommended total cholesterol (TC) and low-density lipoprotein cholesterol 
(LDL-C) levels in high-risk patients treated with atorvastatin monotherapy in the 
UK. MethOds: In this retrospective UK general practice database study, included 
were patients with a prescription for atorvastatin monotherapy (IndexRx) between 
November 30, 2008-November 30, 30, 2011, who had evidence of coronary heart dis-
ease (CHD), atherosclerotic vascular disease (AVD), diabetes mellitus (DM), or familial 
hypercholesterolemia, ≥ 1 TC and LDL-C measurement 3-12 months post-IndexRx, 
and an atorvastatin prescription (to determine the daily dose) within 45 days of lipid 
measurements. Endpoints included proportions of patients (overall and by dose) 
below guideline-specific thresholds: TC< 5.0, TC< 4.0, and for patients with CHD/
AVD+DM, TC< 4.0 or LDL< 2.0 mmol/L. Results: Of 2999 high-risk patients (60.2% 
males, mean age 67.9 years [SD 10.6]) meeting selection criteria, 23.9, 28.2, 36.2, and 
11.6% received prescriptions for 10-mg, 20-mg, 40-mg, and 80-mg atorvastatin, respec-
tively. Further, 27.6% of patients were newly initiated with atorvastatin monotherapy 
at index date. Overall, mean follow-up TC was 4.08 (SD 0.80) and LDL-C was 2.08 (SD 
0.65) mmol/L. The proportion of patients with TC< 5.0 and < 4.0 mmol/L was 88.8% 
and 45.8%, respectively. For those with CHD/AVD+DM, 63.7% had TC< 4.0 or LDL-C< 2.0 
mmol/L. Generally, more patients were below lipid thresholds with higher atorvastatin 
doses. cOnclusiOns: In UK patients at high CV risk, a substantial proportion did 
not achieve guideline-recommended lipid levels. Less than half of patients achieved 
TC< 4.0 mmol/L, and only two-thirds of patients with CHD/AVD+DM were below rec-
ommended levels for either TC or LDL-C. More effective lipid-lowering strategies may 
be needed to achieve optimal TC and LDL-C levels in high-risk patients.
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total number of patients with stable angina who have indications for ivabradine 
was 17559 people. The number of prevented cases of non-fatal myocardial infarc-
tion and unstable angina was 244 cases per year. The number of prevented cases 
of cardiovascular death was 95 cases per year. The number of prevented cases of 
surgical revascularization was 260 cases per year. cOnclusiOns: The analysis 
allowed to identify Belarusian patients in need of ivabradine use by estimating 
the size of the target group of patients with stable angina and elevated heart 
rate for whom antianginal therapy is inadequate or impossible and who need an 
ivabradine prescription and potentially could make the most effective reaction 
to the therapy.
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Objectives: Intermittent pneumatic compression (IPC) is proposed as an adjunct 
to medical care for people with critical limb ischemia (CLI) who are unsuitable for 
revascularisation. Given the lack of treatment options for these patients, a safe 
therapy that can be shown to provide even a modest clinical improvement may 
make a significant contribution to the management of this condition. This research 
aims to synthesise and critically appraise the evidence supporting the use of this 
technology in this cohort. MethOds: A systematic review of the clinical effective-
ness of IPC in non-reconstructable CLI was performed. Medline, Embase and trial 
registries were searched for randomised controlled trials (RCTs), non-randomised 
controlled trials (nRCTs) and controlled before-and-after (CBA) studies compar-
ing IPC plus medical care to medical care only. Results: No RCTs or nRCTs were 
identified. Two CBA studies, both with a high risk of bias, found that IPC was asso-
ciated with improved limb salvage and wound healing (OR 7, 95% CI 1.82 to 26.89, 
p< 0.05 for both outcomes) as well as improved quality of life scores in bodily pain 
(mean difference [MD] 32.7, 95% CI 29.4 to 36.0, p< 0.05) and physical functioning 
(MD 18.8, 95% CI 14.1 to 23.6, p< 0.05). Improvements were also reported for initial 
and absolute claudication distances (MD 26.9m, 95% CI 21.7 to 32.1, p< 0.05; MD 
52.9m, 95% CI 42.2 to 63.6, p< 0.05, respectively). No serious adverse events were 
reported. cOnclusiOns: Despite some promising results there is a lack of high-
quality evidence demonstrating the effectiveness of IPC in addition to medical 
management in non-reconstructable CLI. Where findings are equivocal a question 
arises as to the minimum level of evidence required to support the introduction of 
a technology when no effective alternatives exist. Competing interpretations of the 
balance of risks and benefits between different stakeholders in the decision-making 
process in these circumstances are discussed.
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Objectives: To evaluate excess use of coronary angiography prior to coronary 
artery bypass graft (CABG) surgery and its association with mortality, health care 
costs and hospital quality in Turkey. MethOds: MEDULA, a nationwide integrated 
system shared between general health insurance and health care providers in 
Turkey was used to analyze coronary angiography utilization. Patients age 18–99 
years who underwent CABG surgery between April 1, 2009 and October 1, 2010 were 
identified and assigned to “standard-therapy” or “excess-use” groups based on 
whether they had one or more coronary angiography, respectively, within 3 months 
of the first CABG diagnosis date (index date) during the identification period. 
Survival rates and annual health care costs of patients in the coronary angiog-
raphy standard-therapy and excess-use groups were compared using propensity 
score matching. The empirical Bayes approach was used to combine mortality 
and hospital volume for quality index. Chi-squared tests were used to assess the 
relationship between hospital quality and excess use of coronary angiography 
excess use. Results: From a total of 20,126 identified patients, 7.27% underwent 
excessive coronary angiography procedures, at average annual costs that were 
9.7% higher than patients with a single angiography (p< 0.01). Operational mortal-
ity associated with excessive use was significantly higher as well (7.4% vs. 5.4%, 
p< 0.02). Use of coronary angiography across cities and hospitals varied. Patients 
who underwent cardiac surgery in high-quality hospitals were less likely to have 
excessive angiography use than those in low-quality hospitals (7.0% vs. 9.5%, 
p< 0.01). cOnclusiOns: In Turkey, excess use of coronary angiography prior to 
CABG surgery is associated with higher operational mortality, higher expenditures 
and lower hospital quality.
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Objectives: To examined anticoagulant use and associated factors in hospitalized 
patients with acute venous thromboembolism (VTE) in the US clinical practice set-
ting. MethOds: Adult VTE patients were selected from the linked MarketScan and 
Hospital Drug database in an inpatient setting between 07/01/2006-12/31/2011. The 
first hospitalization with a diagnosis of VTE was designated index hospitalization 
(IH). Patients were required to have at least 6 months continuous enrollment and 
dabigatran and rivaroxaban appear to have better safety and efficacy profiles when 
compared with warfarin. Apixaban and dabigatran 110mg consistently demon-
strated reduced risk of bleeding when compared with rivaroxaban and dabigatran 
150mg. Dabigatran150mg demonstrated increased efficacy on multiple endpoints 
when compared with rivaroxaban, while discontinuation rates were increased. 
Head-to-head studies would help clarify any differences among these medicines 
for efficacy and bleeding.
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Objectives: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have 
shown safety and efficacy for treatment of AF. The objective of this study was 
to conduct meta-analysis and present evidence for safety of Dabigatran versus 
Warfarin for treatment of AF. MethOds: For this meta-analysis we included 
randomized controlled trials (RCTs) evaluating Dabigatran for the treatment of 
AF. We included studies that were: (1) a RCT in humans; (2) an investigation of 
patients with nonvalvular atrial fibrillation; (3) an evaluation of dabigatran com-
pared with warfarin or each other; and (4) a report of results of stroke or systemic 
emboli and major bleeding. A systematic literature search for dabigatran trials 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and 
Cochrane. Data was collected for the study size, interventions, year and total 
bleeding events. For meta-analysis, random effects and fixed effects models were 
used to obtain cumulative statistics. Results: Two RCTs with a total of 12,268 
patients were identified. The pooled event rate for Dabigatran for total bleeding 
events was 31.9% (95% CI 31%-33%). The pooled response rate for Warfarin for 
total bleeding events was 35.1% (95% CI 34%-37%). The cumulative relative risk 
for total bleeding events with Dabigatran versus Warfarin was 0.91 (95% CI 0.89-
0.93) cOnclusiOns: Meta-analysis shows Dabigatran has a slightly lower rate 
of total bleeding events compared to Warfarin.
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Objectives: To evaluate efficacy/safety of ivabradine in chronic stable angina 
pectoris(CSAP) Thai patients. MethOds: Ivabradine 5-7.5 mg bid was prescribed 
to CSAP patients. Hemodynamic parameters including systolic/diastolic blood 
pressure(SBP/DBP) in mmHg and heart rate(HR) in beats per minute(bpm) were 
recorded at entry and after 1,4 months follow-up. A standardized digital device 
was used to monitor BP and HR. Acceptability was evaluated in patient inter-
views. Results: A total of 256 patients, men/women ratio of 1.04, mean(SD) age 
67.1(12.4) years, 149(58%) were > 65 years old, 64(25%) and 76(29.7%) of patients 
had previous intervention and heart failure(HF). 127(50%)&51(20%) received beta-
blockers&nitrate as initial medication. Patients’ assessment was made using 
Canadian Cardiology Society angina pectoris classification(CCS). At entry, 34.9%, 
52.2% and 10.8% of patients were found with CCS grades 3, 2 and 1. Among 76 HF 
patients, 35.8%, 58.2% and 6.0% were found with stage 3, 2 and 1 of NYHA classifica-
tion. In overall population, mean(SD) baseline HR was 86.9(11.2) bpm and SBP/DBP 
137.8(24.6)/81.7(15.9) mmHg. After 4 months, mean(SD), HR significantly reduced to 
69.96(7.13)bpm (p< 0.001) and SBP/DBP lowered to 126.5(12.9)/73.9(8.9) mmHg, while 
mean arterial pressure(MAP)was optimally maintained at 100.4(17.6) mmHg. The 
highly significant drop in mean difference(SE) HR of 16.9(0.7) was observed with 
95% CI between 15.5-18.3 bpm. No significant mean difference(SE),[95% CI] SBP 
drop, between patients with/without HF, and with/without previous intervention 
of 7.32(1.17),[4.99-9.64] and 8.15(2.07),[4.02-12.2764], or 8.14(1.27),[5.61-10.67] and 
7.46(0.89),[5.69-9.22] (p= 0.502, p= 0.691) respectively. Improvement for CCS 3 and 
CCS 2 angina class, reduced to 1.9% and 36.1% whereas the NYHA classification 
for stage 3&2 reduced to 3.2%&56.4%(p< 0.001). Common AE reported were palpita-
tion(2.5%) and nausea(1%). cOnclusiOns: Ivabradine is a well-tolerated heart rate 
reducing agent, effective for both chronic stable angina pectoris and heart failure. 
It effectively reduces elevated heart rate without affecting other hemodynamic 
parameters. In this Thai setting, ivabradine significantly improves CCS and NYHA 
classifications with minimal side effects being reported.
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Objectives: To determine the potential population of patients with stable angina 
pectoris in Belarus who need prescription of ivabradine and setting the amount of 
the effect of the drug in this group of patients. MethOds: In the research phar-
macoeconomic Markov model of ivabradine application in patients with stable 
angina, national surveillance data, analysis of literature have been used. Patients 
with stable angina after revascularization, patients with contraindications to 
beta-blocker use, not applying the dihydropyridines and having a contraindica-
tion to ivabradine use have been used to determine the target population. The 
number of prevented or postponed events – PPE - (nonfatal myocardial infarction 
and unstable angina, cardiovascular death, the number of surgical revasculariza-
tion) has been calculated. For the potential efficacy of ivabradine use in patients 
with stable angina and heart rate ≥ 70 bpm calculating the data about efficacy in 
accordance with the results of the Beautiful study were used Results: The total 
number of patients with stable angina pectoris in Belarus in 2011 was 242943. The 
